论文部分内容阅读
感染、自身免疫紊乱、慢性疾病和年龄等很多原因都会导致炎症发生并发展为贫血。炎症性贫血(anemia of inflammation AI)通常为正细胞正色素性贫血,临床表现温和。系统性的铁利用、红细胞生成、红细胞生存期特征的变化导致了炎症性贫血。最佳治疗是纠正病因,然而当病因不清或难以诊断时,治疗炎症性贫血的办法就非常有限了。铁调素(Hepcidin)是近年研究铁利用调节的中心。由于铁调素定量分析技术的发展,人们逐渐认识到其在各种疾病中的作用。最近研究集中在铁调素表达调节通路,并发现了药物治疗的靶点。由于治疗上的巨大进步,分析正常血红蛋白对疾病预后的影响,就可以明确炎性疾病发生和死亡过程中贫血是否具有可逆性。
Infections, autoimmune disorders, chronic diseases and age can lead to inflammation and anemia. Anemia of inflammation AI is usually positive cell anemia, mild clinical manifestations. Systemic iron utilization, erythropoiesis, changes in the characteristics of erythrocyte survival lead to inflammatory anemia. The best treatment is to correct the cause, however, when the etiology is unclear or difficult to diagnose, the treatment of inflammatory anemia is very limited. Hepcidin is the center of research on iron utilization regulation in recent years. Due to the development of quantitative analysis of hepcidin, people gradually come to realize its role in various diseases. Recent research has focused on the pathway of hepcidin expression and regulation and found the targets of drug therapy. Because of the tremendous advances in treatment, analyzing the effect of normal hemoglobin on the prognosis of the disease can make it clear whether anemia is reversible during the onset of inflammatory disease and death.